Tag Archives: Martin Auster
Credit Suisse Keeps a Buy Rating on BioMarin Pharmaceutical (BMRN)
In a report released today, Martin Auster from Credit Suisse maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price target of $128.00. The company’s shares closed last Thursday at $92.43. According to TipRanks.com, Auster is
Credit Suisse Remains a Hold on Ironwood Pharma (IRWD)
In a report released yesterday, Martin Auster from Credit Suisse maintained a Hold rating on Ironwood Pharma (IRWD – Research Report), with a price target of $12.00. The company’s shares closed last Thursday at $10.32. According to TipRanks.com, Auster is
Sarepta Therapeutics (SRPT) Gets a Buy Rating from Credit Suisse
Credit Suisse analyst Martin Auster maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) yesterday and set a price target of $185.00. The company’s shares closed last Thursday at $126.25. According to TipRanks.com, Auster is a 5-star analyst
Analysts’ Top Healthcare Picks: United Therapeutics (UTHR), Anthem (ANTM)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on United Therapeutics (UTHR – Research Report) and Anthem (ANTM – Research Report) with bullish sentiments. United Therapeutics (UTHR) In a report released
Credit Suisse Maintains a Buy Rating on Acceleron Pharma (XLRN)
In a report released yesterday, Martin Auster from Credit Suisse maintained a Buy rating on Acceleron Pharma (XLRN – Research Report), with a price target of $99.00. The company’s shares closed last Monday at $87.21. According to TipRanks.com, Auster is
MyoKardia (MYOK) Received its Third Buy in a Row
After Cowen & Co. and Morgan Stanley gave MyoKardia (NASDAQ: MYOK) a Buy rating last month, the company received another Buy, this time from Credit Suisse. Analyst Martin Auster maintained a Buy rating on MyoKardia yesterday and set a price
